How to Evaluate an EU CTD Dossier Before In-Licensing a Generic Medicine
written by Dr. Ali Adli
N. H.
P. W.
R. M.
A. D.
V. G.
S. Y.
M. P.
M. P.
L. L.
R. K.
S. G.
J. A.
A. K.
D. C.
Y. G.
R. S.
M. R.
H. U.
S. I.
E. A.
To evaluate an EU CTD dossier before in-licensing, establish exactly which asset is offered; confirm in which EU member states the product is authorised, by which procedure and in whose name; test the bioequivalence and stability data against current EU requirements; identify the manufacturing, importation and batch-release sites; decide who will hold the marketing authorisation; and tie payments to regulatory milestones. The result should be a written list of gaps with an owner, cost and date for each—and a decision to proceed, proceed with conditions, pause or reject.
Generic dossier offers often arrive as a single line in a product list: a molecule, a strength, a dosage form and the words “EU CTD dossier available”. That phrase describes how a file is organised. It does not say that the product is authorised anywhere in the European Union, that it can be released from an EU site or that the rights on offer cover your country.
A dossier is the structured body of quality, non-clinical and clinical information submitted to a medicines authority in support of a marketing authorisation. In the EU it follows the Common Technical Document, which ICH describes as five modules: one region-specific and four intended to be common across regions. See the ICH overview of the CTD.
This guide to dossier in-licensing is written for licensing and business-development teams, EU distributors, companies outside the EU planning to enter it, and regulatory professionals asked to review an offer. The commercial model—price, volume and competition—is covered in GXgate’s apixaban patent-expiry analysis and is not repeated here.
Five questions an EU dossier offer must answer
Resolve these in order. A later answer cannot repair an earlier gap.
What Does an EU CTD Dossier Offer Actually Include?
“EU dossier available” can describe three different transactions. Each gives the buyer a different degree of control.
| Offer | What the buyer receives | What to confirm |
|---|---|---|
| Dossier purchase | Ownership of the technical file and, where they exist, transfer of the authorisations. | That the seller owns every part of the file, including the studies and manufacturing know-how. |
| Dossier licence with supply | The right to obtain and hold an authorisation in your own name, with product supplied by the licensor or its manufacturer. | Member states covered, duration, access to the complete file and what happens if supply stops. |
| Distribution under the seller’s authorisation | The right to sell a product that remains authorised in the seller’s name. | That you accept building a market on an authorisation you do not control. |
Trace ownership back to the origin
The company presenting the offer is not always the company that developed the product. Ask for the chain in writing: who generated the data, who owns it today, and under what agreement the seller may grant the rights it proposes. The bioequivalence study may belong to its original sponsor, and the restricted part of the active-substance file belongs to the API manufacturer. A seller can license only what it controls.
Fix the product scope
Record the active substance, dosage form, every strength, pack type and pack size included. A file that supports two strengths in blister packs does not support a third strength or a bottle. Each omission is either additional development work or a product you cannot sell.
Establish the EU Regulatory Status
“Approved in Europe” is not a status. A member state, a procedure number, an authorisation holder and a date are.
Identify the authorisation route
A generic medicine can reach EU markets by different routes, and the route determines what an in-licensing partner can do next.
| Route | What it produces | What to check |
|---|---|---|
| Centralised procedure | One authorisation valid across the EU, assessed by EMA. | Whether the product was eligible, and who the single holder is. |
| Decentralised or mutual-recognition procedure | National authorisations in the member states included in the procedure. | The reference member state, the countries included and whether yours is one of them. |
| Purely national procedure | An authorisation in one member state. | What would be needed to extend it to other countries. |
EMA explains when it assesses generic applications on its page on generic and hybrid medicines. The decentralised and mutual-recognition procedures are coordinated by the CMDh, whose site links to a public index of products approved through those routes. Check the seller’s claims against that index and the national medicines databases.
If your country was not part of the original procedure, the authorisation does not extend to it. Adding a member state is a further procedure with its own timeline and needs the cooperation of the existing holder.
Read the regulatory history, not only the approval
Request the authorities’ questions and the responses given, any commitments made at approval, and the changes filed since. Unanswered questions and pending changes pass to the licensee along with the product.
Ask also when the product was last sold in each country. EU law contains a sunset clause: EMA describes it as the provision under which an authorisation ceases to be valid if the medicine is not placed on the market within three years of being granted or is removed from the market for three consecutive years. An unused authorisation may be close to lapsing, and may rest on a process never run at commercial scale.
Allow for changing EU rules
The EU is replacing its general pharmaceutical legislation. The European Commission reported political agreement in December 2025; see its reform page. Confirm which rules will apply on your intended submission date before relying on a protection period or procedure quoted by a seller.
Practical test: ask the seller to name one member state where the product is authorised and currently sold, and to provide the public register entry. If that single example cannot be produced, treat every other status claim as unverified.
Review the Bioequivalence and Stability Data
A generic application relies on the reference medicine for safety and efficacy. EMA explains that the applicant usually needs to provide quality information and to demonstrate that the generic produces the same levels of active substance in the body. Those two bodies of evidence decide whether the EU CTD dossier can support your application.
Reference product and protection periods
An EU generic application is built on a reference medicinal product authorised in the Union; EMA’s questions and answers on generic applications address what qualifies. Confirm which reference product the dossier names and where the comparator batches were purchased.
EMA states that a generic application can be submitted only once the reference medicine’s data exclusivity has expired, and that the generic can be marketed only after the marketing-protection period ends. Patents and supplementary protection certificates are a separate, country-specific question. A dossier licence gives access to data; it does not give freedom to launch.
Bioequivalence: is the study still current?
Record the study date, the contract research organisation, the strengths studied and the basis on which any other strength was exempted. Check that the test batch represents the product you would receive: the same formulation, site and process. Where EU authorities have found data-integrity failures at a research organisation, medicines relying on its studies have been suspended or re-examined, so review the inspection record of the study site.
Requirements also move. ICH guideline M13A has applied in the EU to immediate-release solid oral products since 25 January 2025 and supersedes parts of the earlier EMA text, as set out on EMA’s bioequivalence guideline page. Assess an older study against the rules that will apply on your submission date.
Stability: does the data cover your pack and shelf life?
EMA’s guideline on stability testing of existing active substances and related finished products sets out what a generic application should contain. Compare the conditions studied, the pack studied and the shelf life claimed. If the pack you intend to sell differs from the pack on stability, the shelf life is not yet supported.
Turn the review into a gap register
The output should not be an opinion that the dossier is “good”. It should be a register in which every gap has an owner, a cost and a date.
| Gap | Work required | Who closes it | Effect on timeline |
|---|---|---|---|
| Study predates current bioequivalence guidance | Gap assessment; justification or a new study | Agree before signing | Can add many months |
| Target member state not in the original procedure | A further procedure to add the country | Existing holder, with licensee | Runs before any national launch |
| No EU batch-release site named | Appoint an EU importer and release site; regulatory change | Manufacturer and licensee | Blocks supply until approved |
| No EU-established holder or safety system | Set up or contract the required functions | Licensee | Needed before submission |
These rows are illustrations. The real register should be written by the person who will sign the submission.
Check the EU Manufacturing and Batch-Release Chain
An authorisation is granted for a product made at named sites by a described process. The commercial offer must match that description.
List every site named in the file
Ask for the sites responsible for manufacture, packaging, quality-control testing, importation and batch release. Confirm that each will perform that step for your supply, and check its authorisation and GMP certificate in EudraGMDP, the Union database of manufacturing and import authorisations and GMP certificates.
Confirm EU importation and batch certification
Many EU dossiers describe a product made outside the Union. The file must then name an authorised EU importer, and each batch must be certified by a Qualified Person before release, as set out in EU GMP. Ask who the importer and release site are, whether they are part of the offer and what they charge per batch.
Check the pack against EU safety-feature rules
The Falsified Medicines Directive introduced obligatory safety features—a unique identifier and an anti-tampering device—on the outer packaging of medicines within its scope; see the European Commission’s page on falsified medicines. Confirm that the packaging site can apply them.
Confirm the API source and control of change
The file refers to a specific active-substance source, whose documentation must be usable by you as the new applicant. The checks are described in GXgate’s guide to verifying GMP status, CEP, ASMF and DMF support.
If the seller proposes supply from a factory that is not in the dossier, the product is not yet the approved product. The change needs regulatory approval, and someone must pay for and file it. Establish who decides future changes, how much notice is given and who bears the cost. The comparison of API manufacturers, CMOs and CDMOs explains the roles involved.
Confirm Licence Rights and the Marketing Authorisation Holder
Who will hold the authorisation?
If the authorisation is granted in your name, you control the product in that country and carry the holder’s obligations. If it stays with the licensor, you depend on the licensor for every change and renewal. EU law requires the holder to be established in the Union, so a company based elsewhere needs an EU entity or an EU partner to hold the authorisation on agreed terms.
Moving an existing authorisation to another legal entity is a formal procedure. EMA describes it for centrally authorised products in its questions and answers on transfers; national authorities apply their own rules.
Can the holder meet its EU safety obligations?
Holders must operate a pharmacovigilance system. EMA’s good pharmacovigilance practices apply to holders of centrally and nationally authorised medicines alike. A first-time holder should cost this function before signing.
How much of the file will you see?
Some licensors hand over the complete dossier. Others provide a summary and deal with the authority directly on confidential sections. A partial file can be enough for approval, but it limits your ability to answer questions, assess changes and move manufacture later. Agree access and future updates before the fee is paid.
Who else holds rights to the same dossier?
Ask for the existing licensees by member state. The same dossier is often licensed to several companies, which can place an identical product in your market under another name. Exclusivity in one member state also does not stop authorised product from another reaching your customers through parallel trade. State exclusivity by country and tie it to obligations on both sides.
Tie Dossier Licence Terms to Regulatory Outcomes
- Payment milestones. Link instalments to verifiable events: signature, delivery of the complete file, acceptance of the submission, the end of the procedure and the grant of the national authorisation.
- Deficiency support. State who answers authority questions, within how many days and at whose cost.
- Failure to approve. Define what is refunded if the application is refused for a reason that lies in the dossier.
- Supply failure. If the named manufacturer cannot supply, the licence should allow a move to another site, with the documentation needed to do it.
- Maintenance. Allocate the cost of renewals and regulatory changes over the life of the product.
- Quality responsibilities. Agree how complaints, recalls and release decisions are handled; the quality-agreement principles in Part 3 of the API supplier series apply here too.
Warning signs
Pause when the seller describes the product as “approved in Europe” without a member state, holder or procedure number; uses “EU CTD” to imply an authorisation that does not exist; cannot name the EU importer and batch-release site; will not show the bioequivalence report until a fee is paid; cannot explain how it acquired the right to license the file; offers the same member state exclusively to more than one party; or asks for full payment before the complete file is delivered.
Using an EU CTD Dossier Outside the EU
EU dossiers are also licensed for registration in other regions. Three further checks apply. Many importing authorities ask for a certificate of a pharmaceutical product issued under the WHO Certification Scheme, so establish whether the seller can obtain one for the exact product and site. WHO’s stability guideline describes the long-term conditions for different climatic zones, and EU data may not support a hot and humid market. The receiving authority may also require a different comparator, a local study or its own dossier format.
Make One Documented In-Licensing Decision
| Decision | Appropriate meaning |
|---|---|
| Proceed | Ownership, status, sites and holder arrangement are confirmed, and the remaining gaps are minor, costed and assigned. |
| Proceed with conditions | No disqualifying gap exists, but named evidence or actions must be completed before a stated payment or submission milestone. |
| Pause | Ownership, authorisation status, data acceptability, the release site or the holder arrangement remains unclear. |
| Reject | The seller cannot grant the rights offered, the evidence cannot support an EU application at acceptable cost, or information has been withheld or misrepresented. |
A condition should name the action, the responsible party, the evidence of completion and the milestone it blocks. “Seller to provide updated data” is not a condition.
Frequently Asked Questions
What is an EU CTD dossier?
It is a registration file organised in the Common Technical Document structure and prepared to EU requirements. For a generic medicine, its core is the quality documentation and the evidence of bioequivalence to an EU reference product.
What is dossier in-licensing?
It is an agreement under which a company obtains the right to use another company’s registration dossier to obtain or hold a marketing authorisation in defined countries, usually together with a supply agreement for the product.
Does “EU CTD” mean the product is approved in the EU?
No. The term describes the format and intended standard of the file. A dossier may be authorised in several member states, under review, or compiled but never filed. Ask for the authorisation records.
Can a company outside the EU hold an EU marketing authorisation?
The holder must be established in the Union. A company based elsewhere needs its own EU legal entity or an EU partner that holds the authorisation under contract, together with EU-based release and safety functions.
Can a dossier approved in one member state be used in another?
Yes, but not automatically. A national authorisation is valid only in the country that granted it. Extending it requires a further procedure involving the existing holder and the new member state.
Start With a Defined Requirement
The strongest dossier discussions begin with a buyer who can state the molecule, strengths, packs, member states and holder arrangement it needs, and a seller who can answer with records. Evaluate the EU CTD dossier before negotiating the fee: a lower price does not compensate for a study the authorities will not accept or a release site that is not in the authorisation.
Find dossier holders and licensing partners
Explore licensing offers and pharmaceutical companies by product, dosage form, country and target territory.
Public-source review: 13 November 2026. Regulatory statements describe the cited EU guidance in general terms, rather than the requirements for a particular product or member state. EU pharmaceutical legislation is being revised; confirm the current position with the relevant authority and qualified regulatory and legal advisers before committing to a licence. GXgate marketplace and directory listings are a starting point for independent partner evaluation.